Members
In this section
Thank you, 2026 Industry Roundtable members.
The Âé¶¹´«Ã½Ó³» and the Industry Roundtable collaborate on opportunities to support neurology and serve patients with neurological disease.
$75,000 members
$50,000 members




$25,000 members
- Alnylam Pharmaceuticals, Inc.
- Amneal Specialty, a division of Amneal Pharmaceuticals LLC
- Annexon Biosciences
- AstraZeneca
- Bristol Myers Squibb
- C2N Diagnostics
- Immunovant
- Ionis Pharmaceuticals
- Johnson & Johnson
- Neurocrine Biosciences
- Octapharma
- Praxis Precision Medicines, Inc.
- Roche
- Sandoz
- The Global CEO Initiative on Alzheimer's Disease
- Xenon Pharmaceuticals
$10,000 members
- Alkermes
- Avidity Biosciences
- Cognito Therapeutics
- Dianthus Therapeutics
- ITF Therapeutics
- Kyverna Therapeutics
- Stoke Therapeutics
- Vor Biopharma
All grants, sponsorships, and IRT memberships must comply with the Âé¶¹´«Ã½Ó³»’s Principles Governing Academy Relationships with External Sources of Support, the Accreditation Council for Continuing Medical Âé¶¹´«Ã½Ó³» (ACCME) Standards for Commercial Support, and the Council of Medical Specialty Societies’ Code for Interactions with Companies. Âé¶¹´«Ã½Ó³» accepts financial and in-kind support from corporations, foundations, individuals, and other organizations only if such acceptance would not pose a conflict of interest and in no way impair the Âé¶¹´«Ã½Ó³»’s objectivity, influence, priorities, and actions. Support of Âé¶¹´«Ã½Ó³» programs or participation on the IRT does not permit influence over content, nor does it imply Âé¶¹´«Ã½Ó³» approval or endorsement of an organization’s policies or products.